Prostate cancer is the most common genitourinary malignancy among men worldwide. While outcomes for most localized cancers are good, advanced prostate cancer remains a lethal disease. Therefore, improving methods of both localized treatment and treatment of metastatic lesions have been a core focus in the field for prostate cancer patients. One of the emerging treatment technologies is ultra-hypofractionated radiotherapy, also known as stereotactic ablative radiation therapy or stereotactic body radiation therapy (SBRT).
Studies have demonstrated that ablative SBRT targeting oligo-metastases (5 or less) may offer long-term local control without significant adjacent normal tissue toxicity. This targeted approach allows for a higher dose to be utilised compared to conventional fractionated radiotherapy.
The aim of this Research Topic is to provide insight into how SBRT impacts prostate cancer patients, improves the treatment landscape of the disease, and the survival rate. We welcome Original Research Article, Reviews Articles, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Prostate cancer is the most common genitourinary malignancy among men worldwide. While outcomes for most localized cancers are good, advanced prostate cancer remains a lethal disease. Therefore, improving methods of both localized treatment and treatment of metastatic lesions have been a core focus in the field for prostate cancer patients. One of the emerging treatment technologies is ultra-hypofractionated radiotherapy, also known as stereotactic ablative radiation therapy or stereotactic body radiation therapy (SBRT).
Studies have demonstrated that ablative SBRT targeting oligo-metastases (5 or less) may offer long-term local control without significant adjacent normal tissue toxicity. This targeted approach allows for a higher dose to be utilised compared to conventional fractionated radiotherapy.
The aim of this Research Topic is to provide insight into how SBRT impacts prostate cancer patients, improves the treatment landscape of the disease, and the survival rate. We welcome Original Research Article, Reviews Articles, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
